Viemed Q2 FY26 net income falls 12.45% to USD 2.76 million; revenue rises 23.9% to USD 78.1 million
VMD•Quarterly results
Viemed Healthcare Q2 2026 revenue rose 23.9% year over year to USD 78.1 million, setting a quarterly record.
Net income attributable to shareholders fell to USD 2.8 million, or USD 0.07 per diluted share.
Adjusted EBITDA (non-GAAP) slipped 4% to USD 13.7 million, as Q2 2025 included a USD 1 million non-recurring disposal gain.
Patient growth and updated outlook
Ventilator patients climbed 4% from a year earlier to 12,635; PAP therapy patients more than doubled, rising 44% to 37,825.
The company raised its 2026 revenue outlook to USD 314 million-USD 320 million and narrowed its adjusted EBITDA (non-GAAP) forecast to USD 64 million-USD 68 million.
